Neoplasia — MCQs

A 53-year-old woman presents with increasing malaise. Physical examination reveals no abnormalities, but a stool guaiac test is positive. Her hemoglobin level is 7.9 g/dL. Colonoscopy identifies a 3-cm sessile mass in the cecum. Biopsy of the mass shows a moderately differentiated adenocarcinoma confined to the mucosa. Abdominal CT scan shows no lymphadenopathy or hepatic lesions. What is the best course of action?

Q105Easy

Which feature is the most reliable indicator of a malignant tumor?

Q106Medium

All of the following statements about carcinoid syndrome are true EXCEPT?

Q107Easy

Zellballen pattern is seen in which of the following tumors?

Q108Medium

Moderately increased risk of invasive breast carcinoma is associated with which of the following benign breast lesions?

Q109Easy

Which of the following locations can a paraganglioma be seen in?

Q110Easy

What is the tumor marker for dysgerminoma?

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 101: What is the typical nuclear cytoplasmic ratio in malignant cells?

A. 1:6
B. 1:5
C. 1:1 (Correct Answer)
D. 6:4

Explanation: **Explanation:** In pathology, the **Nuclear-Cytoplasm (N:C) ratio** is a critical morphological hallmark used to differentiate benign from malignant cells. [1] **1. Why 1:1 is Correct:** In normal, mature cells, the nucleus is relatively small compared to the volume of the cytoplasm, typically maintaining a ratio of **1:4 or 1:6**. However, malignant cells undergo rapid proliferation and metabolic hyperactivity. This leads to **nuclear enlargement (macronucleosis)** due to increased DNA content (polyploidy/aneuploidy), chromatin redistribution, and enlarged nucleoli. [1] As the nucleus expands to occupy a significant portion of the cell volume, the ratio shifts toward **1:1**. **2. Analysis of Incorrect Options:** * **Options A (1:6) and B (1:5):** These represent the **normal physiological range** for most resting or differentiated human cells. A high volume of cytoplasm relative to the nucleus indicates cellular maturity and specialized function rather than malignancy. * **Option D (6:4):** While malignant nuclei are large, a ratio where the nucleus significantly exceeds the total cell volume (beyond 1:1) is not the standard textbook definition for the **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 276-280.

Question 102: Loss of heterozygosity means?

A. Loss of a single arm of a chromosome.
B. Loss of a mutant allele in a mutant gene.
C. Loss of a normal allele in a normal gene.
D. Loss of a normal allele in a heterozygous gene. (Correct Answer)

Explanation: ### Explanation: Loss of Heterozygosity (LOH) **1. Why Option D is Correct:** Loss of Heterozygosity (LOH) is a critical concept in the **Knudson Two-Hit Hypothesis** of tumor suppressor genes (TSGs). In a heterozygous state, an individual possesses one functional (normal/wild-type) allele and one non-functional (mutant) allele [1]. While the single functional allele is usually sufficient to prevent tumor formation, the **loss or inactivation of this remaining normal allele** leads to the complete loss of gene function, triggering neoplastic transformation [2]. This "second hit" can occur via point mutations, chromosomal deletions, or gene silencing [2]. **2. Analysis of Incorrect Options:** * **Option A:** While the loss of a chromosomal arm (interstitial deletion) is a common *mechanism* by which LOH occurs, LOH specifically refers to the genetic outcome (loss of the allele) rather than just the structural change. * **Option B:** Losing a mutant allele would theoretically restore or maintain normal function; LOH specifically refers to the loss of the "protective" normal allele. * **Option C:** If both alleles are normal (homozygous wild-type), losing one allele results in hemizygosity, but the term LOH is specifically reserved for the transition from a heterozygous state to a homozygous/hemizygous mutant state. **3. Clinical Pearls for NEET-PG:** * **Classic Example:** **Retinoblastoma (*RB1* gene)**. In familial cases, the first hit is inherited (germline), and LOH represents the second hit (somatic) [1, 2]. * **Common Mechanisms of LOH:** Mitotic recombination, nondisjunction, or chromosomal deletion. * **High-Yield Fact:** LOH is often used in research as a marker to map the location of unidentified tumor suppressor genes on specific chromosomes. * **Other TSGs following this pattern:** *TP53* (Li-Fraumeni), *APC* (Familial Adenomatous Polyposis), and *BRCA1/2* (Breast/Ovarian cancer) [1, 2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 227-228. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 298-300.

Question 103: Carcinoid tumors are known to secrete which of the following substances?

A. Histamine
B. VMA (Vanillylmandelic acid)
C. 5-HT (Serotonin) (Correct Answer)
D. Bradykinin

Explanation: **Explanation:** **1. Why 5-HT (Serotonin) is Correct:** Carcinoid tumors are neuroendocrine neoplasms derived from **enterochromaffin (Kulchitsky) cells** [2]. These cells possess the biochemical machinery to decarboxylate amino acids into biogenic amines. The most characteristic substance secreted is **5-hydroxytryptamine (5-HT or Serotonin)** [3], [4]. In the systemic circulation, serotonin causes the classic "Carcinoid Syndrome" (flushing, diarrhea, and wheezing). It is metabolized by the liver into **5-HIAA (5-hydroxyindoleacetic acid)**, which is excreted in the urine and serves as a diagnostic marker. **2. Analysis of Incorrect Options:** * **Histamine (Option A):** While some gastric carcinoids (foregut) can secrete histamine, it is not the primary or most characteristic secretion associated with the classic syndrome compared to Serotonin. * **VMA (Option B):** Vanillylmandelic acid is the urinary metabolite of catecholamines (epinephrine/norepinephrine). It is the diagnostic marker for **Pheochromocytoma** and Neuroblastoma, not carcinoid tumors. * **Bradykinin (Option D):** Though bradykinin and kallikrein contribute to the vasodilation and flushing seen in carcinoid syndrome, they are secondary mediators and not the primary diagnostic secretion of the tumor cells. **3. High-Yield NEET-PG Pearls:** * **Most common site:** Appendix (overall), but the **Ileum** is the most common site to cause Carcinoid Syndrome. * **Rule of Metastasis:** Carcinoid syndrome typically occurs only after the tumor has metastasized to the **liver**, bypassing the "first-pass" metabolism of serotonin [1]. * **Carcinoid Heart Disease:** Characterized by **Tricuspid Regurgitation** and Pulmonary Stenosis (Right-sided lesions) due to fibrous plaque deposition. Left-sided lesions are rare because the lungs contain monoamine oxidase (MAO) which degrades serotonin. * **Stain:** Positive for **Chromogranin A** and Synaptophysin [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 781-782. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 780-781. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, p. 727. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Inflammation and Repair, pp. 94-95.

Question 104: A 53-year-old woman presents with increasing malaise. Physical examination reveals no abnormalities, but a stool guaiac test is positive. Her hemoglobin level is 7.9 g/dL. Colonoscopy identifies a 3-cm sessile mass in the cecum. Biopsy of the mass shows a moderately differentiated adenocarcinoma confined to the mucosa. Abdominal CT scan shows no lymphadenopathy or hepatic lesions. What is the best course of action?

A. Administer a multiagent chemotherapeutic regimen
B. Observe the lesion for further increase in size
C. Remove the entire colon to prevent a recurrence
D. Resect the tumor with adequate margins (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Resect the tumor with adequate margins** The patient presents with **iron-deficiency anemia** (Hb 7.9 g/dL) and a positive stool guaiac test, which in an older adult is highly suggestive of a gastrointestinal malignancy until proven otherwise [4]. Right-sided (cecal) colon cancers often present with occult bleeding rather than obstruction [5]. The biopsy confirms a **moderately differentiated adenocarcinoma**. Although the tumor is currently "confined to the mucosa," adenocarcinomas are malignant by definition and have the potential to invade and metastasize [1]. The standard of care for a localized colonic adenocarcinoma is **surgical resection** with wide margins of apparently normal tissue and regional lymph node evaluation [2]. This provides the best chance for a definitive cure [4]. **Analysis of Incorrect Options:** * **Option A:** Chemotherapy is typically reserved for advanced stages (Stage III/IV) or high-risk Stage II disease. It is not the primary treatment for a localized, resectable mass. * **Option B:** Observation is contraindicated. Malignant tumors do not regress spontaneously; delay in treatment allows for deeper wall invasion and systemic spread. * **Option C:** Total colectomy is overly aggressive and unnecessary. A partial colectomy (right hemicolectomy for a cecal mass) is sufficient to achieve oncological clearance. **Clinical Pearls for NEET-PG:** * **Right-sided vs. Left-sided Colon Cancer:** Right-sided lesions (cecum) usually present with **anemia/occult blood** and are often exophytic [5]. Left-sided lesions (sigmoid) present with **altered bowel habits** or "napkin-ring" obstruction. * **Staging:** The most important prognostic factor for colorectal cancer is the **TNM stage** (depth of invasion and lymph node involvement) [3], [4]. * **Tumor Marker:** **CEA (Carcinoembryonic Antigen)** is used for monitoring recurrence and response to therapy, but *not* for initial screening or diagnosis. * **Histology:** Most colorectal cancers are adenocarcinomas arising from the **adenoma-carcinoma sequence** (APC gene mutation) [5]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 815-817. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 231-232. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 236-237. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 374-375. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 819-821.

Question 105: Which feature is the most reliable indicator of a malignant tumor?

A. Local invasion
B. Metastasis (Correct Answer)
C. Rapid growth
D. Poor differentiation

Explanation: **Explanation:** In pathology, the definitive distinction between benign and malignant tumors rests on their ability to spread beyond the primary site. [1], [2] **1. Why Metastasis is the Correct Answer:** Metastasis is the **most reliable and unequivocal indicator** of malignancy [1]. By definition, benign tumors never metastasize. If a tumor has spread to a distant site (lymph nodes, liver, lungs, etc.) that is not physically continuous with the primary mass, it is categorized as malignant, regardless of its histological appearance. [1], [2] **2. Analysis of Incorrect Options:** * **Local Invasion (Option A):** While local invasion is the *second* most reliable sign of malignancy, it is not absolute [1]. Some benign conditions (e.g., endometriosis or certain aggressive infections) can appear invasive, and some "carcinoma in situ" lesions are malignant but have not yet invaded the basement membrane. * **Rapid Growth (Option C):** Growth rate is unreliable [2]. Some malignant tumors (e.g., low-grade lymphomas) grow very slowly, while some benign tumors (e.g., leiomyomas during pregnancy due to hormonal stimulation) can grow rapidly. * **Poor Differentiation/Anaplasia (Option D):** While anaplasia is a hallmark of malignancy, it is a morphological description [2]. Some highly malignant tumors can be well-differentiated (e.g., Follicular Thyroid Carcinoma), making this less reliable than the physical evidence of metastasis. **Clinical Pearls for NEET-PG:** * **Exceptions:** Not all malignant tumors metastasize. The two classic exceptions are **Basal Cell Carcinoma (BCC)** of the skin and **Gliomas** of the CNS; they are locally invasive but rarely spread distantly. * **Pathways of Spread:** * *Lymphatic:* Most common for Carcinomas. * *Hematogenous:* Most common for Sarcomas (Exceptions: Renal Cell Carcinoma and HCC often spread via veins). * *Seeding:* Common in Ovarian cancers (peritoneal cavity). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 280-282. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 206-207.

Question 106: All of the following statements about carcinoid syndrome are true EXCEPT?

A. Atypical carcinoid syndrome is usually produced by foregut carcinoids.
B. Plasma serotonin levels are normal in atypical carcinoid syndrome.
C. Midgut carcinoids have high serotonin content.
D. Foregut carcinoids are usually argentaffin positive. (Correct Answer)

Explanation: ### **Explanation** Carcinoid tumors are neuroendocrine neoplasms derived from **Kulchitsky cells**. Their clinical behavior and biochemical profile depend on their embryological site of origin (Foregut, Midgut, or Hindgut) [2]. **1. Why Option D is the Correct Answer (The False Statement):** Foregut carcinoids (stomach, lung, duodenum) are typically **Argentaffin negative** but **Argyrophil positive**. * **Argentaffin cells** can reduce silver salts to metallic silver without an external agent (because they contain high serotonin). * **Argyrophil cells** require an external reducing agent. Since foregut carcinoids often lack the enzyme *DOPA decarboxylase*, they produce 5-hydroxytryptophan (5-HTP) rather than pure serotonin, making them argentaffin negative. **2. Analysis of Other Options:** * **Option A:** Atypical carcinoid syndrome (characterized by vivid, patchy, geographic flushing and hypotension) is indeed produced by **foregut carcinoids** due to the release of 5-HTP and histamine [3]. * **Option B:** In atypical carcinoid syndrome, **plasma serotonin levels are often normal** because the tumor lacks the decarboxylase enzyme to convert 5-HTP to serotonin. However, urinary 5-HIAA levels may still be elevated. * **Option C:** **Midgut carcinoids** (ileum, jejunum) are the classic producers of serotonin. They are rich in serotonin and are typically **Argentaffin positive**. --- ### **High-Yield Clinical Pearls for NEET-PG** * **Most Common Site:** The **Appendix** is the most common site for carcinoid tumors overall, but the **Ileum** is the most common site to cause Carcinoid Syndrome [2]. * **The Rule of Metastasis:** Carcinoid syndrome occurs only when the tumor or its metastases bypass the liver's first-pass metabolism (e.g., hepatic metastasis or primary bronchial carcinoid) [1]. * **Diagnosis:** The best screening test is **24-hour urinary 5-HIAA** (a metabolite of serotonin). * **Cardiac Involvement:** Right-sided heart lesions (Tricuspid regurgitation, Pulmonary stenosis) are common. Left-sided lesions are rare because the lungs contain **Monoamine Oxidase (MAO)**, which degrades serotonin. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 781-782. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 780-781. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, p. 727.

Question 107: Zellballen pattern is seen in which of the following tumors?

A. Paragangliomas
B. Pheochromocytoma
C. Carotid body tumor
D. All of the above (Correct Answer)

Explanation: **Explanation:** The **Zellballen pattern** (German for "cell balls") is the characteristic histological arrangement seen in tumors derived from **extra-adrenal paraganglia** and the **adrenal medulla**. 1. **Underlying Concept:** This pattern consists of nests or clusters of polygonal **chief cells** (neurosecretory cells) surrounded by a delicate vascular stroma and peripheral, spindle-shaped **sustentacular cells**. This architecture is the hallmark of all tumors belonging to the paraganglioma family [1]. 2. **Why "All of the Above" is Correct:** * **Pheochromocytoma (Option B):** This is essentially an intra-adrenal paraganglioma. It classically exhibits the Zellballen pattern [1]. * **Paragangliomas (Option A):** This is the general term for these tumors when they occur at extra-adrenal sites (e.g., organ of Zuckerkandl) [2]. * **Carotid Body Tumor (Option C):** This is a specific type of parasympathetic paraganglioma located at the bifurcation of the carotid artery. It also demonstrates the Zellballen architecture. **High-Yield Clinical Pearls for NEET-PG:** * **Staining:** Chief cells are positive for neuroendocrine markers (**Chromogranin** and **Synaptophysin**), while Sustentacular cells are positive for **S-100**. * **Electron Microscopy:** Shows characteristic "dense-core" neurosecretory granules. * **Rule of 10s (Pheochromocytoma):** 10% bilateral, 10% familial, 10% malignant, 10% extra-adrenal, and 10% occur in children [1]. * **Malignancy:** Histology (including the Zellballen pattern) cannot reliably distinguish between benign and malignant tumors; malignancy is defined only by the presence of **metastases** to non-chromaffin sites [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1137-1138. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1137.

Question 108: Moderately increased risk of invasive breast carcinoma is associated with which of the following benign breast lesions?

A. Sclerosing adenosis
B. Atypical lobular hyperplasia (Correct Answer)
C. Apocrine metaplasia
D. Squamous metaplasia

Explanation: The risk of developing invasive breast carcinoma is categorized based on the histological features of benign breast lesions. This classification is a high-yield topic for NEET-PG. **1. Why Atypical Lobular Hyperplasia (ALH) is correct:** ALH falls under the category of **Proliferative disease with atypia**. This category carries a **moderately increased risk** (4 to 5 times) of developing invasive carcinoma [1]. It includes both Atypical Lobular Hyperplasia (ALH) and Atypical Ductal Hyperplasia (ADH) [1]. These lesions are considered clonal precursors to malignancy, though they lack the full architectural criteria for Carcinoma in Situ [1]. **2. Analysis of Incorrect Options:** * **Sclerosing adenosis:** This is a **Proliferative disease without atypia**. It carries a **mildly increased risk** (1.5 to 2 times). Other examples in this category include radial scars and complex sclerosing lesions. * **Apocrine metaplasia:** This is a feature of **Non-proliferative breast changes** (Fibrocystic changes). It carries **no increased risk** (1.0x) of developing breast cancer. * **Squamous metaplasia:** Usually associated with subareolar abscesses (Zuska disease) or infarcts; it is not a precursor to invasive carcinoma and carries **no increased risk**. **3. High-Yield Clinical Pearls for NEET-PG:** * **No Increased Risk (1.0x):** Cysts, Apocrine metaplasia, Mild hyperplasia of usual type, Fibroadenoma (without complex features). * **Slightly Increased Risk (1.5–2.0x):** Sclerosing adenosis, Radial scar, Moderate to florid hyperplasia (usual type), Small duct papillomas. * **Moderately Increased Risk (4.0–5.0x):** ADH and ALH [1]. * **High Risk (8.0–10.0x):** LCIS and DCIS (Carcinoma in situ). * **Note:** The risk associated with atypical hyperplasia is bilateral, meaning it increases the risk of cancer in both the affected and the contralateral breast. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1054-1056.

Question 109: Which of the following locations can a paraganglioma be seen in?

A. Carotid body tumor
B. Thorax
C. Paravertebral location
D. All of the above (Correct Answer)

Explanation: **Explanation:** **Concept:** Paragangliomas are neuroendocrine tumors derived from extra-adrenal chromaffin cells of the autonomic nervous system [1]. These cells are distributed widely throughout the body, following the distribution of the sympathetic and parasympathetic chains. 1. **Carotid Body Tumor (Option A):** This is the most common site for head and neck (parasympathetic) paragangliomas [1]. They typically present as a painless mass at the bifurcation of the carotid artery and are often referred to as "Chemodectomas." 2. **Thorax (Option B):** Paragangliomas can arise from the aorticopulmonary chain or the posterior mediastinum (sympathetic chain) [1]. 3. **Paravertebral Location (Option C):** Sympathetic paragangliomas are frequently found in the retroperitoneum along the paravertebral axis, particularly at the **Organ of Zuckerkandl** (near the origin of the inferior mesenteric artery) [1]. Since paragangliomas can arise in any of these locations, **Option D (All of the above)** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **The 10% Rule:** Historically, 10% of pheochromocytomas were considered extra-adrenal (paragangliomas). However, in pediatric cases, this incidence is higher (~25%). * **Genetics:** Up to 30-40% of paragangliomas are hereditary, often associated with mutations in the **Succinate Dehydrogenase (SDH)** gene complex (SDHB, SDHD) [1], [2]. * **Malignancy:** Unlike adrenal pheochromocytomas, extra-adrenal paragangliomas have a higher risk of malignancy (up to 20-40%). * **Histology:** Characterized by the **"Zellballen" pattern** (nests of polygonal chief cells surrounded by sustentacular cells and a rich vascular network). * **Staining:** Chief cells are positive for **Chromogranin/Synaptophysin**, while sustentacular cells are positive for **S-100**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, pp. 748-749. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1137.

Question 110: What is the tumor marker for dysgerminoma?

A. AFP
B. LDH (Correct Answer)
C. HCG
D. CA-125

Explanation: **Explanation:** **Dysgerminoma** is the most common malignant germ cell tumor of the ovary, occurring primarily in young women [1]. It is the female counterpart of the testicular seminoma [1]. **Why LDH is the correct answer:** Dysgerminomas are characterized by a rapid turnover of cells and a high metabolic rate. **Lactate Dehydrogenase (LDH)** is the classic serum tumor marker for this malignancy. While it is non-specific (as it can be elevated in various conditions), in the context of an adnexal mass in a young female, elevated LDH is highly suggestive of dysgerminoma and is used for both diagnosis and monitoring treatment response. **Analysis of Incorrect Options:** * **AFP (Alpha-Fetoprotein):** This is the characteristic marker for **Yolk Sac Tumors** (Endodermal Sinus Tumors) and Hepatocellular Carcinoma. It is typically normal in pure dysgerminomas. * **HCG (Human Chorionic Gonadotropin):** This is the marker for **Choriocarcinoma**. While a small percentage of dysgerminomas containing syncytiotrophoblastic giant cells may show mild HCG elevation [1], [2], it is not the primary marker. * **CA-125:** This is the primary marker for **Epithelial Ovarian Tumors** (e.g., Serous Cystadenocarcinoma), which usually occur in older, postmenopausal women. **High-Yield Clinical Pearls for NEET-PG:** * **Microscopy:** Look for "Fried egg appearance" (clear cytoplasm, central nuclei) and fibrous septa infiltrated with **T-cell lymphocytes**. * **Associations:** Dysgerminomas are associated with **Gonadal Dysgenesis** (e.g., Turner Syndrome, Swyer Syndrome) [1]. * **Radiosensitivity:** It is the most radiosensitive malignant ovarian tumor [2], though chemotherapy is now the preferred fertility-sparing treatment. * **Other Markers:** **Placental Alkaline Phosphatase (PLAP)** and **c-KIT (CD117)** are also positive in dysgerminomas [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1034-1035. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Female Genital Tract Disease, pp. 480-481.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?